Business Wire

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Share

Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/

From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)

The Hive builds on Almirall's open innovation centre, which began operations in 2023 with collaborations with two life science companies. The arrival of two new joiners announced today contribute to the creation of this unique collaboration ecosystem, following the initial partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products.

The initiative was launched today as part of Almirall's 80th anniversary celebrations, bringing together health authorities, representatives from associations, entities, and institutions with whom Almirall closely collaborates to deliver against its commitment to patients, innovation, and the advancement of healthcare. The new joiners at The Hive include ADmit Therapeutics a company focused on the early detection of Alzheimer’s and other neurodegenerative diseases through technology that combines epigenetic and clinical data using machine learning. The most recent addition is Microomics a company specializing in metagenomic analysis using new DNA sequencing technologies (NGS).

"At Almirall, we bring together scientific experts from different disciplines in a collaborative environment as we see the transformative power collaboration has to push the boundaries of science and drive the development of novel solutions. An open innovation ecosystem that fosters this collaboration lays an exceptional foundation for breakthroughs in both scientific discovery and product development. We are proud to lead the way with The Hive, a unique initiative designed to advance science and innovation. By working together, we can address critical unmet needs and deliver meaningful progress in healthcare, ensuring that our innovations make a tangible difference in the lives of patients and their families", stated Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer.

80 years of innovation and commitment to patients

Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, María José Alonso, professor of Pharmacy and Pharmaceutical Technology at the University of Santiago de Compostela (USC), and Lourdes Borrell, Mayor of Sant Feliu de Llobregat.

Professor María José Alonso congratulated Almirall for its 80 decades “preserving the value of science and its transfer to industry in the best way, contributing to development and well-being, and elevating scientific value in the development of the Spanish innovative ecosystem, fostering a brighter future for all”.

Almirall was founded in Spain in 1944 with the purpose of giving people access to impactful medicines, a goal that continues to guide the company in its ambition as a leading medical dermatology. Almirall´s heritage, its deep scientific expertise, and the strong partnerships with the dermatology community worldwide are the foundation for its broad portfolio of dermatological treatments. Grounded in science and driven by innovation, the company continuously advances the understanding of skin diseases and provides solutions for even the most complex conditions. Based on this dedication, Almirall has become a leader in medical dermatology in Europe, with a strong portfolio of more than 50 products across different modalities, including topical, systemic, and biologics.

The company has invested 1 billion Euros in R&D in medical dermatology in the last decade which represents a continuous investment of over 12% of its annual net sales in R&D. This investment supports all phases of research conducted at its R&D centre – from discovery to late-stage clinical testing. Almirall’s close partnership with patients and dermatologists positions the company as a trusted and reliable partner, as it constantly focuses on understanding their needs to translate these into innovative solutions, helping improve people's lives both physically and emotionally.

Carlos Gallardo, Chairman and CEO of Almirall: "Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our journey has been driven by a profound dedication to improving patients' lives and providing meaningful treatments. As a family-owned company, we think in generations, and have consistently prioritized innovation in medical dermatology, investing over 1 billion Euros in R&D in this area over the last decade. We are grateful for the dedication of our teams across the company, and our partners and collaborators that enable us to help so many patients, every day. Our leading capabilities in skin biology and product development will continue to be a cornerstone of our mission, ensuring our sustained focus on science and innovation to deliver healthcare solutions to patients and the medical community."

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit https://www.almirall.com/

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204100180/en/

Contacts

Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Late-Breaking Tafasitamab (Monjuvi ® ) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma10.12.2024 16:30:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL). These data are featured today in the Late-breaking Session (LBA-1) at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. The late-breaking results, which build on previously announced topline data, show that the study met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in 548 patients with FL. Patients treated with tafasitamab achieved a median PFS by investigator assessment of 22.4 months compared to 13.9 months in the control arm (Hazard Ratio [HR]: 0.43; 95% Confidence

Tacton Announces New CPQ Service Sales Solution to Maximize Lifetime Customer Value for Manufacturers10.12.2024 15:06:00 CET | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software, has launched its innovative Service Sales Solution, to empower manufacturers to manage and sell both products and aftermarket services, deepening customer engagement across the equipment lifecycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209148062/en/ Developed with insights from a leading global manufacturer in the food processing and packaging industry, Tacton’s Service Sales unifies product and service sales in one system. By adopting a solution-selling approach, manufacturers can create optimized packages that streamline operations, enhance efficiency and maximize customer lifecycle value. In today's market, where manufacturers must move beyond standalone product or service sales, Tacton’s Service Sales addresses the growing demand for comprehensive solutions that optimize equipment performance and customer satisfaction. Combining product and se

NetApp’s 2024 Data Complexity Report Reveals AI’s Make or Break Year Ahead10.12.2024 15:00:00 CET | Press Release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today released its second annual Data Complexity Report, which examines how global organizations are navigating the increasing complexity of managing their data for AI. This year’s report provides a global view into how AI will impact organizations in 2025 and beyond, offering insights to help businesses leverage AI’s potential while navigating the complexities and risks that accompany this transformative technology. “2025 is shaping up to be a defining year for AI, as organizations transition from experimentation to scaling their AI capabilities,” said Gabie Boko, Chief Marketing Officer, NetApp. “This year’s Data Complexity Report shows that businesses are making significant investments to drive innovation and efficiency, but these efforts will succeed only if global tech executives can address the mounting challenges of data complexity, security, and sustainability. Intelligent data infrastructure, with unified dat

ClickHouse Announces Strategic Collaboration Agreement with AWS to Advance Real-Time Data Analytics and Generative AI Innovation10.12.2024 15:00:00 CET | Press Release

ClickHouse, Inc., a leader in real-time analytics, announced today that it has signed a five-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to accelerate innovation in real-time data warehousing, observability, business intelligence, machine learning, and generative AI solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210976702/en/ ClickHouse announces strategic collaboration agreement with AWS (Graphic: Business Wire) The partnership will expand on ClickHouse’s relationship with AWS and introduce new integrations between ClickHouse Cloud and AWS services including Amazon Data Firehose, Amazon Relational Database Service (RDS), AWS Glue, and Amazon Bedrock. Together, this will make it easier for customers to build and manage high-performance analytics and generative AI applications. Additionally, this will provide customers with seamless deployment, enhanced interoperability,

Corpay Cross-Border Named the Global FX Partner of UFC10.12.2024 14:30:00 CET | Press Release

Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with UFC, the world's premier mixed martial arts (MMA) organization, to become their official and exclusive Global Foreign Exchange (FX) Partner. "UFC has revolutionized the sport of mixed martial arts, and the team at Corpay Cross-Border is excited to be named their exclusive Global FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “Being recognized as an official partner of a premium global sports brand such as UFC further solidifies Corpay’s position as the currency risk management and cross-border payments solutions company of choice in the world of sports.” “We’re thrilled to welcome Corpay as a first-time UFC partner,” said Nicholas Smith, Vice President of Global Partnerships for TKO. “Corpay provides a valuable service to business looking to streamline the way they manage and pay their exp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye